The Latest: Shkreli jury ends day 1 of deliberations

FILE - In this Thursday, July 27, 2017, file photo, former biotech CEO Martin Shkreli, center, leaves federal court with his attorney Benjamin Brafman, left, in New York. A jury began deliberations Monday, July 31, 2017, at Shkreli's federal securities fraud trial. (AP Photo/Julie Jacobson, File)

NEW YORK — The Latest in the federal securities fraud trial of former pharmaceutical CEO Martin Shkreli (all times local):

5:45 p.m.

Jurors in New York have finished their first day of deliberations in the federal securities fraud trial of former pharmaceutical CEO Martin Shkreli (SHKREL'-ee) without reaching a verdict.

They are expected back on Tuesday to continue deliberating on the charges he faces.

Prosecutors say Shkreli looted his drug company to pay back investors in two failed hedge funds he ran. The defense says investors got their original investments back and even made hefty profits.

The former biotech CEO is best known for hiking up the price of a life-saving drug and for trolling his critics on social media.

If convicted of the most serious counts he could face up to 20 years in prison but likely would receive far less time under sentencing guidelines.

___

10:30 a.m.

Jurors are deliberating in the federal securities fraud trial of former pharmaceutical CEO Martin Shkreli (SHKREL'-ee).

They got the case Monday in New York.

On Friday, they heard closing arguments by prosecutors accusing Shkreli of looting his own drug company to pay back disgruntled investors in two failed hedge funds he ran.

The defense insisted there were no victims because everyone got their original investments back and even made hefty profits.

The 34-year-old Shkreli is best known for jacking up the price of a life-saving drug by 5,000 percent and for trolling his critics online.

___

7:04 a.m.

The federal securities fraud trial of former pharmaceutical CEO Martin Shkreli (SHKREL'-ee) is moving toward the decision-making phase.

Jurors could start deliberating Monday at the trial in New York.

On Friday, they heard closing arguments by prosecutors accusing Shkreli of looting his own drug company to pay back disgruntled investors in two failed hedge funds he ran.

The defense insisted there were no victims because everyone got their original investments back and even made hefty profits.

The 34-year-old Shkreli is best known for jacking up the price of a life-saving drug by 5,000 percent and for trolling his critics online.

Must Read

All Blacks, Wallabies take rivalry off field before 1st test

Aug 18, 2017

An increasingly acrimonious rivalry between the All Blacks and Wallabies has become more pronounced ahead of their first test of the Rugby Championship on Saturday

Paramount inks $1B film co-finance deal with 2 Chinese firms

Jan 20, 2017

Paramount Pictures says it has signed a co-financing deal with two Chinese companies for the Hollywood studio's slate of movies over the next three years

Ali tribute book to be released by Jeter imprint

Aug 11, 2016

A very great athlete will help pay tribute to "The Greatest": Derek Jeter's publishing imprint is set to release "Muhammad Ali Unfiltered." Publication is scheduled for October

People also read these

All Blacks, Wallabies take rivalry off field before 1st test

Aug 18, 2017

An increasingly acrimonious rivalry between the All Blacks and Wallabies has become more pronounced ahead of their first test of the Rugby Championship on Saturday

Paramount inks $1B film co-finance deal with 2 Chinese firms

Jan 20, 2017

Paramount Pictures says it has signed a co-financing deal with two Chinese companies for the Hollywood studio's slate of movies over the next three years

Ali tribute book to be released by Jeter imprint

Aug 11, 2016

A very great athlete will help pay tribute to "The Greatest": Derek Jeter's publishing imprint is set to release "Muhammad Ali Unfiltered." Publication is scheduled for October